Editorial comment on “Wada N, Kita M, Hashizume K, et al. Urodynamic effects of dutasteride add-on therapy to alpha-adrenergic antagonist for patients with benign prostatic enlargement: Prospective pressure-flow study. Neurourol Urodyn 2013;32:1123–7”
- Christopher Chapple led the peer-review process as the Associate Editor responsible for the paper.
- Conflict of interest: Yes, The author is speaker and consultant of Astellas, GlaxoSmithKline (GSK), Lilly, Pfizer, and Recordati.
No abstract is available for this article.